Home » Stocks » AKBA

Akebia Therapeutics, Inc. (AKBA)

Stock Price: $2.84 USD -0.06 (-2.07%)
Updated May 11, 2021 9:36 AM EDT - Market open
Market Cap 473.33M
Revenue (ttm) 259.13M
Net Income (ttm) -392.29M
Shares Out 153.82M
EPS (ttm) -2.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 11
Last Price $2.84
Previous Close $2.90
Change ($) -0.06
Change (%) -2.07%
Day's Open -
Day's Range 2.76 - 2.84
Day's Volume 472,354
52-Week Range 2.09 - 13.71

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -36.36% and 19.43%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

23 hours ago - Zacks Investment Research

Shares of Akebia Therapeutics (NASDAQ:AKBA) fell 1.0% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 4.26% year over year to ($0.45), which missed...

1 day ago - Benzinga

CAMBRIDGE, Mass., May 10, 2021 /PRNewswire/ -- Akebia Therapeutics ® , Inc.

1 day ago - PRNewsWire

Akebia Therapeutics Inc ( AKBA , Financial), Adverum Biotechnologies Inc ( ADVM , Financial) have performed so poorly over the prior 52 weeks through May 5, with the share prices losing more than 59%, t...

Other stocks mentioned: ADVM
4 days ago - GuruFocus

CAMBRIDGE, Mass., May 4, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 9 n...

6 days ago - PRNewsWire

CAMBRIDGE, Mass., April 28, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today an...

1 week ago - PRNewsWire

CAMBRIDGE, Mass., April 28, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today an...

1 week ago - PRNewsWire

NEW YORK, April 26, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty c...

2 weeks ago - PRNewsWire

CAMBRIDGE, Mass., April 12, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today an...

4 weeks ago - PRNewsWire

CAMBRIDGE, Mass., April 2, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 1...

1 month ago - PRNewsWire

Akebia (AKBA) submits new drug application for vadadustat to treat anemia due to chronic kidney disease in adult patients who are on dialysis as well as who are not on dialysis.

1 month ago - Zacks Investment Research

TOKYO & PRINCETON, N.J.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that its collaborator Akebia Therapeutics, Inc. (Akebia) has submitted a New Drug Application (NDA) to the Fo...

1 month ago - Business Wire

CAMBRIDGE, Mass., March 30, 2021 /PRNewswire/ --  Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, tod...

1 month ago - PRNewsWire

CAMBRIDGE, Mass., March 25, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today an...

1 month ago - PRNewsWire

CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA),  today announced that its collaboration partner, Japan Tobacco Inc. (JT), received approval from the Pharmaceut...

1 month ago - PRNewsWire

CAMBRIDGE, Mass., March 11, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, celebrat...

2 months ago - PRNewsWire

With the trading day about halfway over, the broad markets were pushing higher on the day.

Other stocks mentioned: BMBL, NEE, WPM, ARAV, BGNE, IMO, IOVA ...
2 months ago - 24/7 Wall Street

CAMBRIDGE, Mass., March 2, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted f...

2 months ago - PRNewsWire

Investors were not impressed with the drugmaker's latest quarterly update.

2 months ago - The Motley Fool

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Feb. 18, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appo...

2 months ago - PRNewsWire

CAMBRIDGE, Mass., Feb. 2, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 19...

3 months ago - PRNewsWire

With the trading day practically over, the broad markets were sliding into the weekend.

Other stocks mentioned: BIIB, DDD, DUK, F, HOG, LXRX, MTN ...
3 months ago - 24/7 Wall Street

CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today anno...

4 months ago - PRNewsWire

CAMBRIDGE, Mass., Jan. 5, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted ei...

4 months ago - PRNewsWire

Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Dec. 9, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today anno...

5 months ago - PRNewsWire

CAMBRIDGE, Mass., Dec. 2, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 7 ...

5 months ago - PRNewsWire

CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ann...

5 months ago - PRNewsWire

CAMBRIDGE, Mass., Nov. 16, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ann...

5 months ago - PRNewsWire

Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Nov. 3, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 6 ...

6 months ago - PRNewsWire

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Oct. 23, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced the presentation of clinical data from its PRO2TECT global Phase 3 program that evaluated the ef...

6 months ago - PRNewsWire

CAMBRIDGE, Mass., Oct. 22, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced the presentation of clinical data from its global INNO2VATE Phase 3 program, which demonstrated t...

6 months ago - PRNewsWire

Baupost Group leader Seth Klarman (Trades, Portfolio) disclosed earlier this week he divested of his position in Akebia Therapeutics Inc. (NASDAQ:AKBA).

6 months ago - GuruFocus

Akebia Therapeutics (AKBA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Oct. 9, 2020 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that it will present data from its global Phase 3 programs of vadadustat for the treatment of ane...

7 months ago - PRNewsWire

Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Akebia (AKBA) posts top-line data from two phase III studies, namely PRO2TECT, which are evaluating vadadustat for treating anemia due to chronic kidney disease in adults not on dialysis. Shares down.

8 months ago - Zacks Investment Research

On Thursday, Akebia Therapeutics Inc. (NASDAQ: AKBA) announced topline results from the Phase 3 PRO2TECT studies evaluating the safety and efficacy of vadadustat in chronic kidney disease (CKD).

8 months ago - 24/7 Wall Street

The company's lead pipeline candidate fell short in a late-stage clinical study.

8 months ago - The Motley Fool

CAMBRIDGE, Mass., Sept. 3, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc.

8 months ago - PRNewsWire

Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately.

8 months ago - Zacks Investment Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 4.35% and 18.24%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Aug. 10, 2020 /PRNewswire/ -- Top-line data readout of global Phase 3 PRO2TECT program of vadadustat for treatment of anemia due to CKD in adult patients not on dialysis on track for e...

9 months ago - PRNewsWire

CAMBRIDGE, Mass., Aug. 3, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc.

9 months ago - PRNewsWire

CAMBRIDGE, Mass., June 29, 2020 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today an...

10 months ago - PRNewsWire

About AKBA

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis;... [Read more...]

Industry
Biotechnology
IPO Date
Mar 20, 2014
CEO
John Butler
Employees
379
Stock Exchange
NASDAQ
Ticker Symbol
AKBA
Full Company Profile

Financial Performance

In 2020, AKBA's revenue was $295.31 million, a decrease of -11.85% compared to the previous year's $335.00 million. Losses were -$383.46 million, 37.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for AKBA stock is "Buy." The 12-month stock price forecast is 6.71, which is an increase of 136.27% from the latest price.

Price Target
$6.71
(136.27% upside)
Analyst Consensus: Buy